Direkt Links to important GMP Biologic Guidelines

Eudralex Volume 3 GUIDELINE ON ALLERGEN PRODUCTS: PRODUCTION AND QUALITY ISSUES

This document provides principles and guidance for the manufacturing and quality control of allergen products of biological origin, including allergen extracts from natural origin and allergens produced through recombinant DNA technology, used for specific immunotherapy (SIT) or in vivo diagnosis of immunoglobulin E (IgE) mediated allergic diseases.

more

Eudralex Volume 3 CONCEPT PAPER ON THE NEED TO REVISE THE GUIDELINE ON THE USE OF TRANSGENIC ANIMALS IN THE MANUFACTURE OF BIOLOGICAL MEDICINAL PRODUCTS FOR HUMAN USE (3AB7A OF JULY 1995)

This document is concerned with the use of transgenic animals to produce biological pharmaceutical materials for use in human recipients. Transgenic animals may produce higher quantities of material in more concentrated form than existing culture methods, and therefore have considerable advantages in both the cost of producing the starting material and in its downstream processing.

more

Eudralex Volume 3 Requirements for quality documentation concerning biological investigational medicinal products in clinical trials

This guideline outlines the requirements for the data to be presented on the biological, chemical and pharmaceutical quality of Investigational Medicinal Products (IMP) containing biological / biotechnology derived substances.

more

Eudralex Volume 3 Guideline on Real Time Release Testing (formerly Guideline on Parametric Release)

This guideline addresses the requirements for application of RTRT to different kinds of products e.g. chemical and biological products and its scope is to facilitate the introduction of RTR testing. The guideline is a revision of the guideline on parametric release and does not introduce new requirements.

more

Eudralex Volume 3 ICH Guideline Q11 on Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)

This guideline describes approaches to developing process and drug substance understanding and also provides guidance on what information should be provided in CTD sections 3.2.S.2.2 - 3.2.S.2.6. It provides further clarification on the principles and concepts described in ICH guidelines on Pharmaceutical Development (Q8), Quality Risk Management (Q9) and Pharmaceutical Quality Systems (Q10) as they pertain to the development and manufacture of drug substance.

more

FDA Compliance Program Guidance Manual Chapter 42 – Blood and Blood Products Inspection of Source Plasma Establishments, Brokers, Testing Laboratories, and Contractors - 7342.002

This Compliance Program covers Source Plasma, Source Leukocytes, and Therapeutic Exchange Plasma intended for further manufacture into injectable drug products (e.g. immune globulin, albumin) and noninjectable products (e.g. in-vitro devices such as blood bank reagents), which are biological products subject to the licensure provisions of Section 351 of the Public Health Service Act (PHS).

more

FDA Guidance for Industry: Possible Dioxin/PCB Contamination of Drug and Biological Products

This guidance is intended for manufacturers using materials derived from animal sources in the manufacture of human or animal drugs or biological products

more

FDA Guidance for Industry:Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Core Guideline

This guideline applies to pharmaceutical drug substances (i.e., active pharmaceutical ingredients) and pharmaceutical drug products, including marketed chemical, and biotechnological/biological products.

more

FDA Guidance for Industry: Size of Beads in Drug Products Labeled for Sprinkle

This draft guidance provides sponsors of new drug applications (NDAs), abbreviated new drug applications (ANDAs), and biologics licensing applications (BLAs) the Center for Drug Evaluation and Research’s current thinking on appropriate size ranges for beads2 in drug products that are labeled to be administered via sprinkling (e.g., capsules or packets containing beads).

more

Eudralex Volume 10 Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials

requirements for quality documentation concerning biological investigational medicinal products in clinical trials

more

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK